Among adults with prediabetes, lifestyle intervention, but not metformin, was associated with a lower burden of multimorbidity during 21 years of follow-up, which highlights the importance of ...
The FDA has accepted Camurus' resubmitted NDA for CAM2029 (octreotide) extended-release injection for acromegaly, setting a PDUFA date of December 18, 2026.
Prepregnancy obesity was associated with increased risk for preeclampsia and eclampsia, but the magnitude of this risk varies significantly across racial and ethnic groups.